April 9, 2010
The National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)1 for Multaq® (dronedarone) indicating its intention to recommend its use for the management of patients with atrial fibrillation (AF).
October 14, 2009
Sanofi-aventis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq® (dronedarone – 400mg Tablets).
Log in or Register now.
Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.